Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory …
Inflammatory Bowel Disease (IBD) patients have an increased risk of ColoRectal Cancer (CRC). The cumulative risk of CRC development is estimated at 1% after 10 years of disease progression, 2% after 20 years, and 5% after more than 20 years of disease progression (1).
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 800 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Primary outcome (registry wording): To evaluate the prevalence of dysplasia in patients with IBD at high risk of preneoplastic lesions followed prospectively in a screening program at the time of high-definition endoscopes.
Who it is for (from inclusion criteria)
Ages 18 Years to any
Patients age ≥ 18 years
Documented diagnosis of CD or UC established based on standard clinical, endoscopic and histological criteria
IBD patients requiring screening colonoscopy for dysplasia as following:
IBD (CD/UC) evolving for more than 8 years, or for ≥1 year if associated with Primary Sclerosing Cholangitis (PSC)
For UC: Extended ulcerative colitis (E2 or E3 in the Montreal classification)
For CD: Colonic (L2) or ileocolonic (L3) Crohn's disease with \> 50% involvement of the colon
Patient affiliated to the health security system
Who the registry excludes
Patient followed for ileal Crohn's disease (L1)
Patient followed for rectal ulcerative colitis (E1)
Patient referred for a therapeutic endoscopic procedure, without prior or subsequent follow-up in the participating center
Patients \< 18 years old
Patient under guardianship or curatorship
Patient objects to their personal data being used in the context of research
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07719426?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07719426?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.